168 related articles for article (PubMed ID: 35480387)
41. RGD mimetics γ-AApeptides and methods of use (US 20,140,004,039 A1): a patent evaluation.
Wu H; Jiang J; Xu H; Li Q; Cai J
Expert Opin Ther Pat; 2016; 26(1):131-7. PubMed ID: 26560186
[TBL] [Abstract][Full Text] [Related]
42. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
Beck V; Herold H; Benge A; Luber B; Hutzler P; Tschesche H; Kessler H; Schmitt M; Geppert HG; Reuning U
Int J Biochem Cell Biol; 2005 Mar; 37(3):590-603. PubMed ID: 15618016
[TBL] [Abstract][Full Text] [Related]
43. The effect of antagonizing RGD-binding integrin activity in papillary thyroid cancer cell lines.
Cheng W; Feng F; Ma C; Wang H
Onco Targets Ther; 2016; 9():1415-23. PubMed ID: 27042110
[TBL] [Abstract][Full Text] [Related]
44. Novel cilengitide-based cyclic RGD peptides as αvβ
Meena CL; Singh D; Weinmüller M; Reichart F; Dangi A; Marelli UK; Zahler S; Sanjayan GJ
Bioorg Med Chem Lett; 2020 Apr; 30(8):127039. PubMed ID: 32094009
[TBL] [Abstract][Full Text] [Related]
45. Combination of RGD compound and low-dose paclitaxel induces apoptosis in human glioblastoma cells.
Chang MW; Lo JM; Juan HF; Chang HY; Chuang CY
PLoS One; 2012; 7(5):e37935. PubMed ID: 22655084
[TBL] [Abstract][Full Text] [Related]
46. (64)Cu labeled AmBaSar-RGD2 for micro-PET imaging of integrin αvβ3 expression.
Cai H; Li Z; Huang CW; Park R; Conti PS
Curr Radiopharm; 2011 Jan; 4(1):68-74. PubMed ID: 22191616
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3.
Colombo R; Mingozzi M; Belvisi L; Arosio D; Piarulli U; Carenini N; Perego P; Zaffaroni N; De Cesare M; Castiglioni V; Scanziani E; Gennari C
J Med Chem; 2012 Dec; 55(23):10460-74. PubMed ID: 23140358
[TBL] [Abstract][Full Text] [Related]
48. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
49. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
Dal Corso A; Pignataro L; Belvisi L; Gennari C
Curr Top Med Chem; 2016; 16(3):314-29. PubMed ID: 26126915
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and biological evaluation of RGD conjugated with Ketoprofen/Naproxen and radiolabeled with [
Mohammadi R; Shokri B; Shamshirian D; Zarghi A; Shahhosseini S
Daru; 2020 Jun; 28(1):87-96. PubMed ID: 31845157
[TBL] [Abstract][Full Text] [Related]
51. In Vitro and In Vivo Efficacy of Self-Assembling RGD Peptide Amphiphiles for Targeted Delivery of Paclitaxel.
Saraf P; Li X; Wrischnik L; Jasti B
Pharm Res; 2015 Sep; 32(9):3087-101. PubMed ID: 26063045
[TBL] [Abstract][Full Text] [Related]
52. Molecular determinants of arg-gly-asp ligand specificity for beta3 integrins.
Kunicki TJ; Annis DS; Felding-Habermann B
J Biol Chem; 1997 Feb; 272(7):4103-7. PubMed ID: 9020120
[TBL] [Abstract][Full Text] [Related]
53. Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.
Wang X; Shirke A; Walker E; Sun R; Ramamurthy G; Wang J; Shan L; Mangadlao J; Dong Z; Li J; Wang Z; Schluchter M; Luo D; Wang Y; Stauffer S; Brady-Kalnay S; Hoimes C; Lee Z; Basilion JP
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33499427
[TBL] [Abstract][Full Text] [Related]
54. Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors.
Zhai C; Franssen GM; Petrik M; Laverman P; Summer D; Rangger C; Haubner R; Haas H; Decristoforo C
Mol Imaging Biol; 2016 Oct; 18(5):758-67. PubMed ID: 26905697
[TBL] [Abstract][Full Text] [Related]
55. Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy.
Lee S; Lee Y; Kim H; Lee DY; Jon S
Biomacromolecules; 2018 Jun; 19(6):2270-2277. PubMed ID: 29712433
[TBL] [Abstract][Full Text] [Related]
56. A small molecule drug conjugate (SMDC) of DUPA and a duocarmycin built on the solid phase.
Beekman AM; Cominetti MMD; Cartwright OC; Boger DL; Searcey M
Medchemcomm; 2019 Dec; 10(12):2170-2174. PubMed ID: 32879717
[TBL] [Abstract][Full Text] [Related]
57. Structural analysis of integrin recognition and the inhibition of integrin-mediated cell functions by novel nonpeptidic surrogates of the Arg-Gly-Asp sequence.
Greenspoon N; Hershkoviz R; Alon R; Varon D; Shenkman B; Marx G; Federman S; Kapustina G; Lider O
Biochemistry; 1993 Feb; 32(4):1001-8. PubMed ID: 8093840
[TBL] [Abstract][Full Text] [Related]
58. Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging.
Yang J; Guo H; Miao Y
Nucl Med Biol; 2010 Nov; 37(8):873-83. PubMed ID: 21055617
[TBL] [Abstract][Full Text] [Related]
59. Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative.
Temming K; Meyer DL; Zabinski R; Senter PD; Poelstra K; Molema G; Kok RJ
Mol Pharm; 2007; 4(5):686-94. PubMed ID: 17683157
[TBL] [Abstract][Full Text] [Related]
60. RGD binding to integrin alphavbeta3 affects cell motility and adhesion in primary human breast cancer cultures.
Georgoulis A; Havaki S; Drosos Y; Goutas N; Vlachodimitropoulos D; Aleporou-Marinou V; Kittas C; Marinos E; Kouloukoussa M
Ultrastruct Pathol; 2012 Dec; 36(6):387-99. PubMed ID: 23181508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
